Eisai Garners FDA Approval for Liposarcoma Treatment

The FDA has greenlighted Eisai’s Halaven chemotherapy for the treatment of unresectable or metastatic liposarcoma.

Halaven is the first drug approved to treat liposarcoma that has shown improvement in survival time, according to Richard Pazdur, director of the Office of Hematology and Oncology Products in CDER.

A 143-patient trial of the drug demonstrated a median overall survival of 15.6 months compared with 8.4 months for those who received dacarbazine.